Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients (CONTRAST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00205556|
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : January 21, 2011
|Condition or disease||Intervention/treatment||Phase|
|End-stage Renal Disease Cardiovascular Disease||Procedure: on-line hemodiafiltration Procedure: low flux hemodialysis||Not Applicable|
Today, an increasing number of patients with chronic renal failure (CRF) is treated with (on-line) hemodiafiltration (HDF). This practice is based on the assumption that the high incidence of cardiovascular (CV) disease, as observed in patients with CRF, is at least partially related to the retention of uremic toxins in the middle and large-middle molecular (MM) range. As HDF lowers these molecules more effectively than HD, it has been suggested that this treatment improves CV outcome, if compared to standard HD.
Thus far, no definite data on the effects of HDF on CV parameters and/or clinical end-points are available. Promising data include a reduction of left ventricular mass index (LVMi) after one year of treatment with acetate free bio-filtration (AFB). Furthermore, relatively high survival rates were reported in a single center non-experimental study on patients who were treated with HDF, if compared to the EDTA registry data on HD-treated patients. Yet, these data are of observational nature, with the possibility of being biased by confounding by indication.
As the accumulation of MMW substances has been implicated in increased oxidative stress and endothelial dysfunction, a reduction of these compounds might improve these derangements. In addition, cardiac dysfunction, atherosclerosis (as measured by left ventricular mass index [LVMi], carotid intima media thickness [CIMT]) and vascular stiffness (as measured by pulse wave velocity [PWV]) might be reduced during HDF, as compared to low-flux HD.
Therefore, we propose a prospective, randomized multicenter trial, comparing (on-line) HDF with HD. After a stabilization period, an expected number of 700 chronic HD patients will be randomized to either HDF or low-flux HD and followed during 1-6 years. Primary end points are all cause mortality and combined CV events and mortality. In addition, LVMi, PWV, CIMT and various parameters of oxidative stress, acute phase reaction (APR) and endothelial function will be assessed and compared between treatment groups.
This study will provide strong evidence on the efficacy of HDF compared to low flux HD on CV morbidity and mortality, which is currently lacking but urgently needed. It is highly likely that the outcome of this study will affect current clinical practice considerably, in the Netherlands as well as internationally. Moreover, the study will point towards the mechanisms underlying the effects of HDF.
The following hypotheses will be tested:
- All-cause mortality and combined CV morbidity and mortality in patients treated with (on-line) HDF is lower than in patients treated with standard low-flux HD.
- A reduction in MMW uremic toxins by HDF leads to an improvement of the 'uremic profile' (as measured by AGE-levels, homocysteine levels, oxidative stress, and endothelial dysfunction), if compared to standard low-flux HD.
- The improvement of the 'uremic profile' in HDF-treated patients results in an improvement of endothelial function with a reduction in the progression of vascular injury (as measured by CIMT and PWV) and a reduction in LVMi, if compared to standard low-flux HD.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||715 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Increased Convective Clearance by On-line Hemodiafiltration on All Cause and Cardiovascular Mortality in Chronic Hemodialysis Patients: The Dutch Convective Transport Study (CONTRAST)|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||January 2011|
1: low flux hemodialysis
Procedure: low flux hemodialysis
|Active Comparator: 2 on-line hemodiafiltration||
Procedure: on-line hemodiafiltration
addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
- all cause mortality [ Time Frame: entire follow up (until dead or end of study, 1-7 years) ]
- fatal and non-fatal cardiovascular events [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]
- Left ventricular mass index (LVMi), carotid IMT (intima media thickness), aortic pulse wave velocity (PWV) [ Time Frame: first 3 years ]
- laboratory markers of endothelial dysfunction, micro-inflammation, oxidative stress [ Time Frame: first three years of follow up ]
- lipid profiles, uremic toxins [ Time Frame: first three years ]
- quality of life [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]
- nutritional state [ Time Frame: entire follow up (until death or end of study 1-7 years) ]
- anemia management [ Time Frame: first 12 months of follow up ]hemoglobin levels, erythropoietin use / resistance iron saturation / ferritin levels, prescription of iron medication
- cost utility analysis [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]
- hospital admissions [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]hospitalization days hospital admission for infections hospital admission for any cause
- blood pressure and antihypertensive medication [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]
- residual kidney function [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]
- mineral bone disease [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]laboratory parameters of mineral bone disease and medication (phosphate binders, vitamin D (or analogues), cinacalet)
- parameters of treatment / treatment delivery [ Time Frame: entire follow up (until death or end of study, 1-7 years) ]dialysis efficiency (Kt/V urea); bloodflow, dialysate flow, ultrafiltration volume, (HDF:) convection volume
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00205556
|Study Director:||Menso J Nubé, MD PhD||Medical Center Alkmaar|
|Study Chair:||Piet M ter Wee, MD PhD||Vrije Universiteit Medical Center, Amsterdam|
|Study Chair:||Peter J Blankestijn, MD PhD||Universityr Medical Center Utrecht|
|Study Director:||René A van den Dorpel, MD PhD||Medisch Centrum Rijnmond Zuid - locatie Clara, Rotterdam|
|Study Director:||Michiel L Bots, MD PhD||Julius Center for Health Sciences and Primary Care, Utrecht|
|Principal Investigator:||Muriel PC Grooteman, MD PhD||Vrije Universiteit Medical Center, Amsterdam|